Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

References

• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Decraecker M, Toulouse C, Blanc JF. Is there still a place for tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma at the time of immunotherapies? A focus on lenvatinib. Cancers. 2021;13(24):6310. doi:10.3390/cancers13246310
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Torrens L, Montironi C, Puigvehí M, et al. Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology. 2021;74(5):2652–2669. doi:10.1002/hep.32023
   PubMed Web of Science ®Google Scholar
• Liu XF, Zhu XD, Feng LH, et al. Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model. Exp Hematol Oncol. 2022;11(1):20. doi:10.1186/s40164-022-00275-0
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.
   PubMed Web of Science ®Google Scholar
• Jin H, Shi Y, Lv Y, et al. EGFR activation limits the response of liver cancer to lenvatinib. Natur. 2021;595(7869):730–734. doi:10.1038/s41586-021-03741-7
   PubMed Web of Science ®Google Scholar
• Fu R, Jiang S, Li J, Chen H, Zhang X. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. Med Oncol. 2020;37(4):24. doi:10.1007/s12032-020-01350-4
   PubMed Web of Science ®Google Scholar
• Wei CY, Zhu MX, Zhang PF, et al. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2022;77(1):163–176. doi:10.1016/j.jhep.2022.02.019
   PubMed Web of Science ®Google Scholar
• Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res. 2021;149:63–101.
   PubMed Web of Science ®Google Scholar
• Chen CY, Wu SM, Lin YH, et al. Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer. Theranostics. 2019;9(8):2361–2379. doi:10.7150/thno.29628
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu D, Zhang T, Xia L. FGF/FGFR signaling in hepatocellular carcinoma: from carcinogenesis to recent therapeutic intervention. Cancers. 2021;13(6):1.
   Web of Science ®Google Scholar
• Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a Review in Hepatocellular Carcinoma. Drugs. 2019;79(6):665–674. doi:10.1007/s40265-019-01116-x
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: a Literature Review. Pharmaceuticals. 2021;14(1). doi:10.3390/ph14010036
   Web of Science ®Google Scholar
• Zhao Y, Zhang YN, Wang KT, Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188391. doi:10.1016/j.bbcan.2020.188391
   PubMed Web of Science ®Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4–5):441–467. doi:10.1016/j.cytogfr.2005.05.010
   PubMed Web of Science ®Google Scholar
• Lorusso L, Pieruzzi L, Biagini A, et al. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther. 2016;9:6467–6477. doi:10.2147/OTT.S84625
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212(2):139–148. doi:10.1084/jem.20140559
   PubMed Web of Science ®Google Scholar
• Donne R, Lujambio A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology. 2023;77(5):1773–1796. doi:10.1002/hep.32740
   PubMed Web of Science ®Google Scholar
• Wang DX, Yang X, Lin JZ, et al. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: a retrospective, real-world study conducted in China. World J Gastroenterol. 2020;26(30):4465–4478. doi:10.3748/wjg.v26.i30.4465
   PubMed Web of Science ®Google Scholar
• Welland S, Leyh C, Finkelmeier F, et al. Real-world data for lenvatinib in hepatocellular carcinoma (ELEVATOR): a retrospective multicenter study. Liver Cancer. 2022;11(3):219–232. doi:10.1159/000521746
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Kurosaki M, Sakamoto A, et al. The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers. 2021;13(11):2608. doi:10.3390/cancers13112608
   PubMed Web of Science ®Google Scholar
• Lee J, Han JW, Sung PS, et al. Comparative analysis of lenvatinib and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma: a multi-center, propensity score study. J Clin Med. 2021;10(18):1.
   Web of Science ®Google Scholar
• Zhao M, Pan X, Yin Y, et al. Cost-effectiveness analysis of five systemic treatments for unresectable hepatocellular carcinoma in China: an economic evaluation based on network meta-analysis. Front Public Health. 2022;10:869960. doi:10.3389/fpubh.2022.869960
   PubMed Web of Science ®Google Scholar
• Zhou T, Wang X, Cao Y, et al. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res. 2022;22(1):1367. doi:10.1186/s12913-022-08661-4
   PubMed Web of Science ®Google Scholar
• Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev. 2021;101:102227. doi:10.1016/j.ctrv.2021.102227
   PubMed Web of Science ®Google Scholar
• Rizzo A, Dadduzio V, Ricci AD, et al. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs. 2022;31(4):371–378. doi:10.1080/13543784.2021.1948532
   PubMed Web of Science ®Google Scholar
• Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970. doi:10.1200/JCO.20.00808
   PubMed Web of Science ®Google Scholar
• Mo DC, Luo PH, Huang SX, Wang HL, Huang JF. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review. Int Immunopharmacol. 2021;91:107281. doi:10.1016/j.intimp.2020.107281
   PubMed Web of Science ®Google Scholar
• Wu WC, Lin TY, Chen MH, et al. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs. 2022;40(4):789–797. doi:10.1007/s10637-022-01248-0
   PubMed Web of Science ®Google Scholar
• Li Q, Cao M, Yuan G, et al. Lenvatinib plus camrelizumab vs. lenvatinib monotherapy as first-line treatment for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. Front Oncol. 2022;12:809709. doi:10.3389/fonc.2022.809709
   PubMed Web of Science ®Google Scholar
• Wei F, Huang Q, He J, Luo L, Zeng Y. Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: a short-term prognostic study. Cancer Manag Res. 2021;13:4233–4240. doi:10.2147/CMAR.S304820
   PubMed Web of Science ®Google Scholar
• Huang X, Xu L, Ma T, et al. Lenvatinib plus immune checkpoint inhibitors improve survival in advanced hepatocellular carcinoma: a retrospective study. Front Oncol. 2021;11:751159. doi:10.3389/fonc.2021.751159
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Kim BK, Cheon J, Kim H, et al. Atezolizumab/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. Cancers. 2022;14(7):1.
   Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Tada T, et al. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib. Cancer Med. 2022;2022:1.
   Google Scholar
• Niizeki T, Tokunaga T, Takami Y, et al. Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a propensity score matching analysis. Target Oncol. 2022;17(6):643–653. doi:10.1007/s11523-022-00921-x
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–1501. doi:10.1136/gutjnl-2019-318934
   PubMed Web of Science ®Google Scholar
• Tsurusaki M, Murakami T. Surgical and locoregional therapy of HCC: TACE. Liver Cancer. 2015;4(3):165–175. doi:10.1159/000367739
   PubMed Web of Science ®Google Scholar
• Chen CT, Liu TH, Shao YY, Liu KL, Liang PC, Lin ZZ. Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma. Int J Mol Sci. 2021;22(23):12880. doi:10.3390/ijms222312880
   PubMed Web of Science ®Google Scholar
• Fu Z, Li X, Zhong J, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15(3):663–675. doi:10.1007/s12072-021-10184-9
   PubMed Web of Science ®Google Scholar
• Endo K, Kuroda H, Abe T, et al. Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization. Hepatol Res. 2021;51(10):1082–1086. doi:10.1111/hepr.13665
   PubMed Web of Science ®Google Scholar
• Sun L, Xu X, Meng F, et al. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a review. Front Oncol. 2022;12:980214. doi:10.3389/fonc.2022.980214
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Yokosuka O, et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):424–432. doi:10.1016/S2468-1253(18)30078-5
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2022;2022:Jco2200392.
   Google Scholar
• Zhu Y, Sun P, Wang K, et al. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell Int. 2021;21(1):503. doi:10.1186/s12935-021-02200-7
   PubMed Web of Science ®Google Scholar
• He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13:17588359211002720. doi:10.1177/17588359211002720
   Web of Science ®Google Scholar
• Qu S, Zhang X, Wu Y, et al. Efficacy and safety of TACE combined with lenvatinib plus PD-1 inhibitors compared with TACE alone for unresectable hepatocellular carcinoma patients: a prospective cohort study. Front Oncol. 2022;12:874473. doi:10.3389/fonc.2022.874473
   PubMed Web of Science ®Google Scholar
• Cai M, Huang W, Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2022;13:848387. doi:10.3389/fimmu.2022.848387
   PubMed Web of Science ®Google Scholar
• Liu Y, Qiao Y, Zhou M, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. Cancer Med. 2022;2022:1.
   Google Scholar
• Chen S, Wu Z, Shi F, et al. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol. 2022;148(8):2115–2125. doi:10.1007/s00432-021-03767-4
   PubMed Web of Science ®Google Scholar
• Chen S, Xu B, Wu Z, et al. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. BMC Cancer. 2021;21(1):1126. doi:10.1186/s12885-021-08858-6
   PubMed Web of Science ®Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, Phase II trial. Eur J Cancer. 2022;174:68–77. doi:10.1016/j.ejca.2022.07.005
   PubMed Web of Science ®Google Scholar
• Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma. Front Oncol. 2021;11:618206. doi:10.3389/fonc.2021.618206
   PubMed Web of Science ®Google Scholar
• Qu WF, Ding ZB, Qu XD, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 2022;6(5). doi:10.1093/bjsopen/zrac114
   PubMed Web of Science ®Google Scholar
• Guo P, Pi X, Gao F, et al. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: a propensity score matching study. Front Oncol. 2022;12:945915. doi:10.3389/fonc.2022.945915
   PubMed Web of Science ®Google Scholar
• Xiang YJ, Wang K, Yu HM, et al. Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma. Hepatol Res. 2022;52(8):721–729. doi:10.1111/hepr.13773
   PubMed Web of Science ®Google Scholar
• Li X, Fu Z, Chen X, et al. Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in China real-world. Front Oncol. 2022;12:950266. doi:10.3389/fonc.2022.950266
   PubMed Web of Science ®Google Scholar
• Qiao ZY, Zhang ZJ, Lv ZC, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review. Front Immunol. 2021;12:653437. doi:10.3389/fimmu.2021.653437
   PubMed Web of Science ®Google Scholar
• Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479–485. doi:10.1038/bjc.2012.581
   PubMed Web of Science ®Google Scholar
• Hu B, Zou T, Qin W, et al. Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma. Cancer Res. 2022;82(20):3845–3857. doi:10.1158/0008-5472.CAN-21-4140
   PubMed Web of Science ®Google Scholar
• Huang M, Long J, Yao Z, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res. 2023;83(1):89–102. doi:10.1158/0008-5472.CAN-22-0963
   PubMed Web of Science ®Google Scholar
• Wang L, Yang Q, Zhou Q, et al. METTL3-m(6)A-EGFR-axis drives lenvatinib resistance in hepatocellular carcinoma. Cancer Lett. 2023;559:216122. doi:10.1016/j.canlet.2023.216122
   PubMed Web of Science ®Google Scholar
• Lu Y, Shen H, Huang W, et al. Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance. Cell Death Discov. 2021;7(1):359. doi:10.1038/s41420-021-00747-y
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zhang D, Wu F, et al. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med. 2021;25(1):549–560. doi:10.1111/jcmm.16108
   PubMed Web of Science ®Google Scholar
• Sun D, Liu J, Wang Y, Dong J. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Front Oncol. 2022;12:944537. doi:10.3389/fonc.2022.944537
   PubMed Web of Science ®Google Scholar
• Huang S, Ma Z, Zhou Q, et al. Genome-wide CRISPR/Cas9 library screening identified that DUSP4 deficiency induces lenvatinib resistance in hepatocellular carcinoma. Int J Biol Sci. 2022;18(11):4357–4371. doi:10.7150/ijbs.69969
   PubMed Web of Science ®Google Scholar
• Hou W, Bridgeman B, Malnassy G, et al. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC. Hepatol Commun. 2022;6(7):1786–1802. doi:10.1002/hep4.1928
   PubMed Web of Science ®Google Scholar
• Wei L, Lee D, Law CT, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun. 2019;10(1):4681. doi:10.1038/s41467-019-12606-7
   PubMed Web of Science ®Google Scholar
• Zhao Z, Song J, Zhang D, Wu F, Tu J, Ji J. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib. Life Sci. 2021;264:118642. doi:10.1016/j.lfs.2020.118642
   PubMed Web of Science ®Google Scholar
• Guo J, Zhu P, Ye Z, et al. YRDC mediates the resistance of lenvatinib in hepatocarcinoma cells via modulating the translation of KRAS. Front Pharmacol. 2021;12:744578. doi:10.3389/fphar.2021.744578
   PubMed Web of Science ®Google Scholar
• Han T, Zheng H, Zhang J, et al. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis. Cell Death Dis. 2022;13(3):200. doi:10.1038/s41419-022-04652-9
   PubMed Web of Science ®Google Scholar
• Myojin Y, Kodama T, Maesaka K, et al. ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma. Clin Cancer Res. 2021;27(4):1150–1161. doi:10.1158/1078-0432.CCR-20-3382
   PubMed Web of Science ®Google Scholar
• Pan J, Zhang M, Dong L, et al. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy. 2022;2022:1–15.
   Google Scholar
• Arechederra M, Bazai SK, Abdouni A, et al. ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol. 2021;74(4):893–906. doi:10.1016/j.jhep.2020.11.008
   PubMed Web of Science ®Google Scholar
• Han TS, Hur K, Cho HS, Ban HS. Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma. Cancers. 2020;12(9):2622. doi:10.3390/cancers12092622
   PubMed Web of Science ®Google Scholar
• Wei Y, Wei L, Han T, Ding S. miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4α. Carcinogenesis. 2022;43(10):1002–1014. doi:10.1093/carcin/bgac067
   PubMed Web of Science ®Google Scholar
• Xu X, Jiang W, Han P, Zhang J, Tong L, Sun X. MicroRNA-128-3p mediates lenvatinib resistance of hepatocellular carcinoma cells by downregulating c-Met. J Hepatocell Carcinoma. 2022;9:113–126. doi:10.2147/JHC.S349369
   PubMed Web of Science ®Google Scholar
• Hao X, Zhang Y, Shi X, et al. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ. J Exp Clin Cancer Res. 2022;41(1):281. doi:10.1186/s13046-022-02494-z
   PubMed Web of Science ®Google Scholar
• Zhang P, Sun H, Wen P, Wang Y, Cui Y, Wu J. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Mol Ther Nucleic Acids. 2022;27:293–303. doi:10.1016/j.omtn.2021.12.001
   PubMedGoogle Scholar
• Yu T, Yu J, Lu L, et al. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis. Cell Oncol. 2021;44(4):821–834. doi:10.1007/s13402-021-00605-0
   Web of Science ®Google Scholar
• Duan A, Li H, Yu W, Zhang Y, Yin L. Long noncoding RNA XIST promotes resistance to lenvatinib in hepatocellular carcinoma cells via epigenetic inhibition of NOD2. J Oncol. 2022;2022:4537343. doi:10.1155/2022/4537343
   PubMed Web of Science ®Google Scholar
• Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110. doi:10.1186/s13046-018-0777-4
   PubMed Web of Science ®Google Scholar
• Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. doi:10.1371/journal.pone.0212513
   PubMed Web of Science ®Google Scholar
• Adachi Y, Kamiyama H, Ichikawa K, et al. Inhibition of FGFR reactivates IFNγ signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res. 2022;82(2):292–306. doi:10.1158/0008-5472.CAN-20-2426
   PubMed Web of Science ®Google Scholar
• Deng H, Kan A, Lyu N, et al. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer. 2021;9(6):e002305. doi:10.1136/jitc-2020-002305
   PubMed Web of Science ®Google Scholar
• Mok EHK, Leung CON, Zhou L, et al. Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma. Cancer Res. 2022;82(17):3102–3115. doi:10.1158/0008-5472.CAN-21-2934
   PubMed Web of Science ®Google Scholar
• Toh TB, Lim JJ, Hooi L, Rashid M, Chow EK. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma. J Hepatol. 2020;72(1):104–118. doi:10.1016/j.jhep.2019.08.035
   PubMed Web of Science ®Google Scholar
• Ma XL, Hu B, Tang WG, et al. CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol. 2020;13(1):11. doi:10.1186/s13045-020-0845-z
   PubMed Web of Science ®Google Scholar
• Chen G, Wang Y, Zhao X, et al. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation. J Exp Clin Cancer Res. 2021;40(1):218. doi:10.1186/s13046-021-02011-8
   PubMed Web of Science ®Google Scholar
• Wang J, Yu H, Dong W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/β-catenin and hippo signaling pathways. Gastroenterology. 2023;164(6):990–1005. doi:10.1053/j.gastro.2023.01.041
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med. 2019;8(1):137–146. doi:10.1002/cam4.1909
   PubMed Web of Science ®Google Scholar
• Lin PT, Teng W, Jeng WJ, Lin CY, Lin SM, Sheen IS. Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol. 2022;34(2):213–219. doi:10.1097/MEG.0000000000001956
   PubMed Web of Science ®Google Scholar
• Guan R, Yu C, Li S, Mei J, Wei W, Guo R. A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Front Pharmacol. 2022;13:998534. doi:10.3389/fphar.2022.998534
   PubMed Web of Science ®Google Scholar